A phase I study of TPI 287, a novel taxane, administered every 21 days in patients (pts) with advanced cancer
Autor: | P. Plezia, L. Pugliese, Manuel Modiano, Y. Baram, S. Yancik, M. Basche, S. Silberman, Allen Lee Cohn, Gilles Tapolsky |
---|---|
Rok vydání: | 2008 |
Předmět: | |
Zdroj: | Journal of Clinical Oncology. 26:13510-13510 |
ISSN: | 1527-7755 0732-183X |
DOI: | 10.1200/jco.2008.26.15_suppl.13510 |
Popis: | 13510 Background: TPI 287 is a novel taxane engineered to overcome multi-drug resistance. In preclinical studies, TPI 287 suppressed the growth of multiple human tumor xenografts in nude mice, including xenografts that expressed mdr-1 and were resistant to other taxanes. The safety and tolerability of TPI 287 when administered every 21 days was examined in this Phase 1 dose escalation study in pts with advanced cancers. Methods: TPI 287 was administered over 1 hour every 21 days in ascending doses to groups of 3 pts. Treatment cohorts were expanded to 6 pts in the face of dose-limiting toxicity (DLT); pts could remain on study until the development of progressive disease or an intolerable adverse event. The maximum tolerated dose (MTD) was defined as the dose at which < 2/3 of pts experienced DLT. Results: 21 pts (M:F 5:9, median age 58.5, range 49 - 77) were enrolled in 5 dose levels ranging from 56 - 185 mg/m2. Pts’ cancers included colorectal (7 pts), pancreatic (2), NSCLC (2), breast (2) and one each ... |
Databáze: | OpenAIRE |
Externí odkaz: |